Veracyte’s approach to prostate cancer testing
EXCEPTIONAL TESTING FOR PROSTATE CANCER
Better treatment planning with the Decipher® Prostate Genomic Classifier
Veracyte developed the Decipher Prostate Genomic Classifier to help physicians and their patients with prostate cancer determine the best treatment plan. The test does this by determining how aggressive the patient’s cancer is and identifying how likely the cancer is to metastasize. Armed with this information, the physician may recommend less intensive treatment or earlier, more intensive treatment.2-16 Decipher Prostate was developed using whole-transcriptome analysis and machine learning and is performed on a sample taken during biopsy or surgical removal of the prostate.
Learn about Decipher Prostate for prostate cancer
American Cancer Society. Cancer Facts & Figures 2023.
Vince Jr RA, et al. Prostate Cancer Prostatic Dis. 2021.
Kim HL, et al. Prostate Cancer Prostatic Dis. 2019.
Herlemann A, et al. Prostate Cancer Prostatic Dis. 2020
Berlin A, et al. Int J Radiat Oncol Biol Phys. 2019.
Spratt DE, et al. J Clin Oncol. 2018.
Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Prostate Cancer V.1.2023. © National Comprehensive Cancer Network, Inc. 2023. All rights reserved. Accessed [June 20, 2023]. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. NCCN = National Comprehensive Cancer Network® (NCCN®).
Spratt DE, et al. J Clin Oncol. 2022.
Nguyen PL, et al. Prostate Cancer Prostatic Dis. 2017.
Nguyen PL, et al. Int J Radiat Oncol Biol Phys. 2023.
Den RB, et al. J Clin Oncol. 2015.
Ross AE, et al. Prostate Cancer Prostatic Dis. 2016.
Marascio J, et al. Prostate Cancer Prostatic Dis. 2019.
Feng FY, et al. JAMA Oncol. 2021.
Spratt DE, et al. Eur Urol. 2018.
Dal Pra A, et al. Ann Oncol. 2022.
The Decipher Prostate Genomic Classifier is available in the US as part of Veracyte’s CLIA-validated laboratory developed test (LDT) service. This test has not been cleared or approved by the FDA.
This website contains information on products that are targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for you accessing such information that may not comply with any legal process, regulation, registration or usage in the country of your origin.